Background/Aims Tenofovir disoproxil fumarate (TDF) is known to have a lipid-lowering effect. This is in contrast to tenofovir alafenamide (TAF), which has a lipid-neutral effect. Therefore, concerns have been raised as to whether these differences affect long-term cardiovascular risk. Here, we aimed to evaluate the long-term risk of cardiovascular events in chronic hepatitis B (CHB) patients treated with TAF or TDF.
Methods We retrospectively analyzed 4,124 treatment-naïve CHB patients treated with TDF (n=3,186) or TAF (n=938) between 2012 and 2022. The primary outcome was a composite endpoint of major adverse cardiovascular events (MACE), including myocardial infarction, ischemic stroke, and hospitalization for unstable angina or heart failure. Serial changes in lipid profiles between two treatments were also explored.
Results The median age of the patients was 50.6 years, and 60.6% of the patients were male. At baseline, 486 (11.8%) and 637 (15.4%) of the patients had dyslipidemia and fatty liver, respectively. A total of 42 MACE occurred, with an annual incidence of 0.2%/100 person-years (PYs). At 1, 3, and 5 years, the cumulative risk of MACE was 0.4%, 0.8%, and 1.2% in patients treated with TDF, and 0.2%, 0.7%, and 0.7% in patients treated with TAF, respectively (p=0.538). No significant differences in the risk of MACE were observed between TDF and TAF. A multivariable analysis found that current smoker and a history of cardiovascular events were risk factors associated with an increased risk of MACE.
Conclusions Patients treated with TAF had comparable risks of cardiovascular outcomes, defined as MACE, as patients treated with TDF.
Citations
Citations to this article as recorded by
Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment Grace Lai‐Hung Wong, Edward Gane, Calvin Q. Pan, Scott Fung, Mang M. Ma, Namiki Izumi, Shalimar, Seng Gee Lim, Wan‐Long Chuang, Rajiv Mehta, Young‐Suk Lim, Leland J. Yee, John F. Flaherty, Frida Abramov, Hongyuan Wang, Maria Buti Alimentary Pharmacology & Therapeutics.2026; 63(1): 132. CrossRef
Atherosclerotic Cardiovascular Risk in Patients with Chronic Hepatitis B: Tenofovir Disoproxil Fumarate Vs. Tenofovir Alafenamide: A Korean Nationwide Study Jiwon Yang, Jihye Lim, Ye‐jee Kim, Hwa Jung Kim, Jonggi Choi Journal of Medical Virology.2026;[Epub] CrossRef
Evaluating fracture risk with TDF in elderly patients with hepatitis B: A Korean perspective Yoon E. Shin, Jae Young Kim, Jeong Ju Yoo, Sang Gyune Kim, Young Seok Kim Journal of Hepatology.2025; 82(6): e301. CrossRef
Tenofovir Disoproxil Fumarate Versus Entecavir: Effects on Lipid Profiles and Cardiovascular Outcomes in People Living With Chronic Hepatitis B Log Young Kim, Jae Young Kim, Jeong‐Ju Yoo, Sang Gyune Kim, Young‐Seok Kim Journal of Medical Virology.2025;[Epub] CrossRef
Safety of tenofovir alafenamide in the context of hyperlipidemia and cardiovascular diseases: a nationwide analysis Jae-Young Kim, Hyuk Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim Hepatology International.2025; 19(4): 959. CrossRef
Impact of Tenofovir Alafenamide on Lipid Profiles in Chronic Hepatitis B Patients: Systematic Review and Meta‐Analysis Ping‐Yu Hsu, Hui‐Chen Su, Mi‐Chia Ma, Chien‐An Chen, Sin‐Yi Yu, Yi‐Ming Hua Journal of Medical Virology.2025;[Epub] CrossRef
Effect of switching from prior Nucleos(t)ide Analogue(s) to Tenofovir alafenamide on lipid profile and cardiovascular risk in patients with Chronic Hepatitis B Witchayaporn Praguylertluck, Apichat Kaewdech, Naichaya Chamroonkul, Teerha Piratvisuth, Pimsiri Sripongpun, Tyng-Yuan Jang PLOS One.2025; 20(5): e0324897. CrossRef
Metabolic effects and cardiovascular disease risks of TDF or TAF in patients with chronic hepatitis B: a systematic review and meta-analysis Yuan-Hai Zhou, Nan Cai, Yu-Xin Chen, Yong-Lu Su, Peng Hu Frontiers in Pharmacology.2025;[Epub] CrossRef
Comparison of bone mineral density changes between denosumab and bisphosphonates in tenofovir-exposed chronic hepatitis B patients with osteoporosis Yunmi Ko, Byeong Geun Song, Hyunjae Shin, Youngsu Park, Jeayeon Park, Min Kyung Park, Yun Bin Lee, Su Jong Yu, Dong Hyun Sinn, Yoon Jun Kim, Jung-Hwan Yoon, Seung Shin Park, Moon Haeng Hur, Jeong-Hoon Lee Osteoporosis International.2025; 36(8): 1391. CrossRef
Blood pressure and metabolic outcomes after efavirenz‐ or dolutegravir‐based therapy started in acute HIV infection Phillip Chan, Sarah Moreland, Carlo Sacdalan, Donn J. Colby, Ferron Ocampo, Pathariya Promsena, Somchai Sriplienchan, Jarawee Wattana, Jintana Intasan, Nittaya Phanuphak, Sandhya Vasan, Robert Paul, Lydie Trautmann, Serena Spudich, Eugène Kroon HIV Medicine.2025; 26(10): 1619. CrossRef
Pharmacovigilance analysis of metabolic and nutritional adverse reactions associated with entecavir and tenofovir using the FDA adverse event reporting system database Haomin Zhu, Baolong Ding, Zhuying Jing, Hongting Yao, Yue Li, Lihong Gao, Yulu Zhu, Xin Li International Journal of Clinical Pharmacy.2025; 47(5): 1510. CrossRef
Antiviral Therapy Reduces Dyslipidemia and Cardiovascular Risk in Chronic Hepatitis B: TDF as the Most Effective Agent Hyuk Kim, Jae‐Young Kim, Hyun Bin Choi, Ji‐Soo Lee, Yoon E. Shin, Jeong‐Ju Yoo, Sang Gyune Kim, Young‐Seok Kim Journal of Medical Virology.2025;[Epub] CrossRef
Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated With Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate Jiwon Yang, Jihye Lim, Ye‐Jee Kim, Hwa Jung Kim, Jonggi Choi Liver International.2025;[Epub] CrossRef
Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer – author’s reply Hyeyeon Hong, Jonggi Choi Clinical and Molecular Hepatology.2024; 30(2): 272. CrossRef
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer Pin-Nan Cheng, Ming-Lung Yu Clinical and Molecular Hepatology.2024; 30(2): 144. CrossRef
Lipid safety of tenofovir alafenamide during 96-week treatment in treatment-naive chronic hepatitis B patients Wenjuan Zhao, Yi Liu, Mengdi Zhang, Zixin Cui, Zhan Qu, Yiyang Li, Meijuan Wan, Wen Wang, Yunru Chen, Lei Shi, Jianzhou Li, Feng Ye Frontiers in Medicine.2024;[Epub] CrossRef
Reply to correspondence on “Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide” Pin-Nan Cheng, Ming-Lung Yu Clinical and Molecular Hepatology.2024; 30(4): 1031. CrossRef
Effects of tenofovir alafenamide fumarate on serum lipid profiles in patients with chronic hepatitis B Fei Cao, Tao Fan, Xue Jiang, Jian Wang, Yilin Liu, Li Zhu, Ye Xiong, Shaoqiu Zhang, Zhiyi Zhang, Yifan Pan, Yuanyuan Li, Chao Jiang, Juan Xia, Xiaomin Yan, Jie Li, Xingxiang Liu, Chuanwu Zhu, Rui Huang, Chao Wu Virology Journal.2024;[Epub] CrossRef
Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials Maria Buti, Young‐Suk Lim, Henry Lik Yuen Chan, Kosh Agarwal, Patrick Marcellin, Maurizia R. Brunetto, Wan‐Long Chuang, Harry L. A. Janssen, Scott K. Fung, Namiki Izumi, Maciej S. Jablkowski, Dzhamal Abdurakhmanov, Frida Abramov, Hongyuan Wang, Irina Botr Alimentary Pharmacology & Therapeutics.2024; 60(11-12): 1573. CrossRef
Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra
Clin Mol Hepatol 2023;29(Suppl):S286-S301. Published online December 28, 2022
Non-alcoholic fatty liver disease (NAFLD) is currently the fastest growing indication to liver transplantation (LT) in Western Countries, both for end stage liver disease and hepatocellular carcinoma. NAFLD/non-alcoholic steatohepatitis (NASH) is often expression of a systemic metabolic syndrome; therefore, NAFLD/NASH patients require a multidisciplinary approach for a proper pre-surgical evaluation, which is important to achieve a post-transplant outcome comparable to that of other indications to LT. NAFLD/NASH patients are also at higher risk of post-transplant cardiovascular events, diabetes, dyslipidemia, obesity, renal impairment and recurrent NASH. Lifestyle modifications, included diet and physical activity, are key to improve survival and quality of life after transplantation. A tailored immunosuppressive regimen may be proposed in selected patients. Development of new drugs for the treatment of recurrent NASH is awaited.
Citations
Citations to this article as recorded by
Deep learning-enhanced quantitative evaluation of hepatic ischemia–reperfusion injury and steatosis via near-infrared hyperspectral imaging Zichen Wang, Zhan Qu, Chen Chen, Jian Du, Jian Zhang, Tao Li, Jianhua Shi, Chun Zhang, Jianwen Lu, Min Tian, Lu Lu, Boyan Tian, Zhen Zhao, Fan Mu, Lexuan Xu, Xin Zhang, Yimeng Wang, Cuiping Yao, Hao Sun, Yi Lyu, Bo Wang, Liangshuo Hu International Journal of Surgery.2026;[Epub] CrossRef
Examining the prevalence of hepatic steatosis and advanced fibrosis using non-invasive measures across Canada: A national estimate using the Canadian Health Measures Survey (CHMS) from 2009-2019 Jacob Romano, Jessica Burnside, Giada Sebastiani, Alnoor Ramji, Keyur Patel, Mark Swain, Sahar Saeed Annals of Hepatology.2025; 30(1): 101757. CrossRef
Macronutrient Modulation in Metabolic Dysfunction-Associated Steatotic Liver Disease—the Molecular Role of Fatty Acids compared with Sugars in Human Metabolism and Disease Progression Sinéad M Mullin, Aidan J Kelly, Méabh B Ní Chathail, Suzanne Norris, Christopher E Shannon, Helen M Roche Advances in Nutrition.2025; 16(3): 100375. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease: Pathogenetic Links to Cardiovascular Risk Vlad Alexandru Ionescu, Gina Gheorghe, Nicolae Bacalbasa, Camelia Cristina Diaconu Biomolecules.2025; 15(2): 163. CrossRef
Metabolic dysfunction-associated steatotic liver disease correlates with higher lower graft survival in liver transplant recipients with hepatocellular carcinoma Marwan Alsaqa, Leandro Sierra, Ana Marenco-Flores, Ximena Parraga, Romelia Barba, Daniela Goyes, N. Begum Ozturk, Michael P. Curry, Alan Bonder, Behnam Saberi European Journal of Gastroenterology & Hepatology.2025; 37(4): 497. CrossRef
Clinical and Economic Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Spanish Mediterranean Region: A Population-Based Study Javier Díaz Carnicero, Inma Saurí-Ferrer, Josep Redon, Jorge Navarro, Gonzalo Fernández, Carlos Hurtado, Karine Ferreira, Carolina Alvarez-Ortega, Antón Gómez, Carlos J. Martos-Rodríguez, David Martí-Aguado, Desamparados Escudero, Marta Cedenilla Journal of Clinical Medicine.2025; 14(7): 2441. CrossRef
MASLD or MAFLD: fatty liver by any name will pose the same challenge Anil Chandra Anand, Dibyalochan Praharaj Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Correspondence to letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation” Soon Kyu Lee, Jong Young Choi Clinical and Molecular Hepatology.2025; 31(2): e212. CrossRef
Risk Factors Related to the Development of Nonalcoholic Fatty Liver: A Systematic Review Omaira Valencia, Carolina López, Esteban Vanegas-Duarte, Carolina Fillizola, Diana Fernanda Bejarano Ramírez, Nicolás Andrés Cortés Mejía, Alonso Vera Torres, Kevork M. Peltekian Canadian Journal of Gastroenterology and Hepatology.2025;[Epub] CrossRef
Safety, efficacy, and outcomes of invasive coronary angiography in liver transplant candidates Carme Ginard, Giulia Pagano, Salvatore Brugaletta, Annabel Blasi, Marta Sánchez-Ric, Ander Regueiro, Roger Pujol, Sergio Rodriguez-Tajes, Pablo Ruiz, Jordi Colmenero, Gonzalo Crespo JHEP Reports.2025; 7(7): 101428. CrossRef
The Relationships Between MASLD, Extrahepatic Multimorbidity, and All-Cause Mortality in the UK Biobank Cohort Qi Feng, Chioma N Izzi-Engbeaya, Andrea D Branch, Benjamin H Mullish, Pinelopi Manousou, Mark Woodward The Journal of Clinical Endocrinology & Metabolism.2025; 111(1): e58. CrossRef
MAFLD as a Cardiovascular Risk Factor: An Extended Retrospective Study with a Control Group Małgorzata Szymala-Pędzik, Marcin Piersiak, Maciej Pachana, Karolina Lindner-Pawłowicz, Wioletta Szczepaniak, Małgorzata Sobieszczańska Journal of Clinical Medicine.2025; 14(12): 4181. CrossRef
Metabolic-associated fatty liver disease: Noninvasive diagnosis and assessment of liver fibrosis O. O. Karshina, I. S. Sabirov Meditsinskiy sovet = Medical Council.2025; (8): 72. CrossRef
Are we standing on the shifting sands of post-transplant metabolic-associated steatotic liver disease? Renata Zatta, Luana S da Silva, Guilherme Felga, Carolina FMG Pimentel World Journal of Hepatology.2025;[Epub] CrossRef
Corrected T1 (cT1) is the most appropriate diagnosis and monitoring tool for widespread adoption of resmetirom treatment in the United States Marika Hancock, Cayden Beyer, Michael Fuchs, Mukesh Harisinghani, Prasun Jalal, Michael Ndaa, Niharika Samala, Jose D. Vargas, Arjun Jayaswal Journal of Medical Economics.2025; 28(1): 1370. CrossRef
Metabolic dysfunction-associated steatotic liver disease management in Saudi Arabia: A modified Delphi-based adaptation of international standards Faisal Abaalkhail, Faisal M. Sanai, Khalid AlSwat, Adnan Alzanbagi, Ahmed Aljedai, Ali Alshehri, Assim Alfadda, Hamdan Alghamdi, Majid Almadi, Mohammad Aleissa, Mona Ismail, Saud Alsifri, Turki Alzahrani, Saleh Alqahtani, Waleed Al Hamoudi Saudi Journal of Gastroenterology.2025;[Epub] CrossRef
Integrated Genomic Analysis Reveals the Synergistic Role of PNPLA3 and ABCC8 Variants in Diabetic MASLD in Pakistan Asma Shabbir, Ambrina Khatoon, Zaigham Abbas, Sucheta Srivastava, Talat Mirza Medical Sciences.2025; 13(3): 178. CrossRef
Sex-Stratified Prediction Models for 5-Year Nonalcoholic Fatty Liver Disease Risk in Thyroid Cancer Patients: A Nationwide Cohort Study Young Bin Cho, Kyoung Sik Park Biomedicines.2025; 13(9): 2250. CrossRef
Genome-Based Mexican Diet Bioactives Target Molecular Pathways in HBV, HCV, and MASLD: A Bioinformatic Approach for Liver Disease Prevention Leonardo Leal-Mercado, Arturo Panduro, Alexis José-Abrego, Sonia Roman International Journal of Molecular Sciences.2025; 26(18): 8977. CrossRef
Validation of MELD 3.0 and ReMELD-Na scoring systems: a German clinical cohort study Aghnia J. Putri, Decan Jiang, Zoltan Czigany, Arianeb Mehrabi, Markus Wolfgang Buechler, Uta Merle, Christoph Michalski, Peri Husen Langenbeck's Archives of Surgery.2025;[Epub] CrossRef
A Multi-Modal Deep Fusion Network: Enhancing Graft Survival Prediction in Non-Alcoholic Fatty Liver Disease Patients Prior to Liver Transplantation Devi Rajeev, S Remya, Anand Nayyar IEEE MultiMedia.2025; 32(4): 68. CrossRef
Investigating the Effect of Two Types of Aerobic Exercise on SIRT1 and AMPK Gene Expression Regulation in an Animal Model of Non-Alcoholic Fatty Liver Disease Masoumeh Sadat Foroughi Rahaghi, Lida Moradi, Bahram Abedi, Mohammad Ali Azarbaijani Journal of Shahrekord University of Medical Sciences.2025; 27(4): 192. CrossRef
How best to combine liver transplantation and bariatric surgery?—Results from a global, web‐based survey Jeannette Widmer, Janina Eden, Fariba Abbassi, Roberta Angelico, Fabian Rössler, Beat Müllhaupt, Philipp Dutkowski, Marco Bueter, Andrea Schlegel Liver International.2024; 44(2): 566. CrossRef
Exploring the effects of epigallocatechin gallate on lipid metabolism in the rat steatotic liver during normothermic machine perfusion: Insights from lipidomics and RNA sequencing Shuxuan Li, Yao Zhi, Wentao Mu, Mingqian Li, Guoyue Lv European Journal of Pharmacology.2024; 964: 176300. CrossRef
Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond Allison Soto, Colby Spongberg, Alessandro Martinino, Francesco Giovinazzo Biomedicines.2024; 12(2): 397. CrossRef
Metabolic dysfunction-associated steatotic liver disease: A silent pandemic Arghya Samanta, Moinak Sen Sarma World Journal of Hepatology.2024; 16(4): 511. CrossRef
Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients David Pérez Compte, Lucas Etourneau, Anne-Marie Hesse, Alexandra Kraut, Justine Barthelon, Nathalie Sturm, Hélène Borges, Salomé Biennier, Marie Courçon, Marc de Saint Loup, Victoria Mignot, Charlotte Costentin, Thomas Burger, Yohann Couté, Christophe Bru Biomarker Research.2024;[Epub] CrossRef
Cardiac abnormalities pre- and post-liver transplantation for metabolic dysfunction-associated steatohepatitis – Evidence and special considerations Steven M. Elzein, Elizabeth W. Brombosz, Sudha Kodali Journal of Liver Transplantation.2024; 15: 100228. CrossRef
Serum Creatinine as an Independent Predictor of Moderate to Severe Fibrosis in Chinese American Non-obese Metabolic Dysfunction-Associated Steatotic Liver Disease Michael Sun, Vincent J Yao, Aivi A Rahman, Kevin Liu, Saud Rehman, Amber Sun, Alan C Yao Cureus.2024;[Epub] CrossRef
Recent trends and new developments in liver transplantation Yasuhiko Sugawara, Taizo Hibi BioScience Trends.2024; 18(3): 206. CrossRef
Cenicriviroc Suppresses and Reverses Steatohepatitis by Regulating Macrophage Infiltration and M2 Polarization in Mice Guanliang Chen, Yanwen Yu, Yuqin Zhu, Mayumi Nagashimada, Yajiao Wang, Naoto Nagata, Liang Xu Endocrinology.2024;[Epub] CrossRef
Metabolic bariatric surgery, alcohol misuse and liver cirrhosis: a narrative review Matthew L. Basa, Danielle S. Cha, David P. Mitchell, Daniel L. Chan Metabolism and Target Organ Damage.2024;[Epub] CrossRef
The interrelation of cardiometabolic risk factors and metabolic dysfunction-associated steatotic liver disease subtypes A. Yu. Ishchenko, M. Yu. Galushko, I. G. Bakulin Meditsinskiy sovet = Medical Council.2024; (15): 146. CrossRef
Cardio-metabolic disorders in a patient with non-alcoholic fatty liver disease and normal body weight Svetlana V. Turkina, Mikhail E. Statsenko, Irina A. Tyshchenko, Marina N. Titarenko, Marina A. Kosivtsova, Elena E. Gorbacheva Journal of Volgograd State Medical University.2024; 21(3): 109. CrossRef
Exploring the knowledge and attitudes towards metabolic dysfunction associated fatty liver disease (MAFLD): Validation and correlations of MAFLD-knowledge questionnaire and MAFLD-attitude questionnaire Samah Al Tawil, Mohamad Abdelkhalik, Adam El Fouani, Nour Allakiss, Lama Mattar, Wissam H. Faour, Rajaa Chatila Heliyon.2024; 10(22): e40217. CrossRef
Weight Loss After Sleeve Gastrectomy According to Metabolic Dysfunction-Associated Steatotic Liver Disease Stage in Patients with Obesity: A Liver Biopsy-Based Prospective Study José Ignacio Martínez-Montoro, Isabel Arranz-Salas, Carolina Gutiérrez-Repiso, Ana Sánchez-García, Luis Ocaña-Wilhelmi, José M. Pinazo-Bandera, Diego Fernández-García, Araceli Muñoz-Garach, Dieter Morales-García, Miren García-Cortés, Eduardo García-Fuente Nutrients.2024; 16(22): 3857. CrossRef
Liver transplantation for alcohol-related liver disease in Korea: The need for patient management guidelines Soon Kyu Lee Annals of Liver Transplantation.2024; 4(2): 40. CrossRef
Post-transplant complications in alcohol- and metabolic-associated steatotic liver disease Shekhar Singh Jadaun, Sanjiv Saigal Metabolism and Target Organ Damage.2024;[Epub] CrossRef
How to optimize the outcome of liver transplantation for non-alcoholic fatty liver disease Byeong Geun Song, Dong Hyun Sinn Clinical and Molecular Hepatology.2023; 29(2): 411. CrossRef
Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies Qingfu Dong, Haolin Bao, Jiangang Wang, Wujiang Shi, Xinlei Zou, Jialin Sheng, Jianjun Gao, Canghai Guan, Haoming Xia, Jinglin Li, Pengcheng Kang, Yi Xu, Yunfu Cui, Xiangyu Zhong Frontiers in Medicine.2023;[Epub] CrossRef
Diabetes and Metabolic Disorders: Their Impact on Cardiovascular Events in Liver Transplant Patients Simone Di Cola, Giulia Cusi, Lucia Lapenna, Jakub Gazda, Stefano Fonte, Marco Mattana, Gianluca Mennini, Patrizio Pasqualetti, Manuela Merli, Xingshun Qi Canadian Journal of Gastroenterology and Hepatology.2023; 2023: 1. CrossRef
Evaluation and Management of Nutritional Consequences of Chronic Liver Diseases Silvia Espina, Diego Casas-Deza, Vanesa Bernal-Monterde, María José Domper-Arnal, Sandra García-Mateo, Alberto Lué Nutrients.2023; 15(15): 3487. CrossRef
New Developments and Challenges in Liver Transplantation Amjad Khalil, Alberto Quaglia, Pierre Gélat, Nader Saffari, Hassan Rashidi, Brian Davidson Journal of Clinical Medicine.2023; 12(17): 5586. CrossRef
Outcomes in elderly patients undergoing hepatic resection compared to liver transplant for hepatocellular carcinoma Sameer A. Khan, Fasih A. Ahmed, Muhammad S. Hafeez, Lawrence R. Feng, Abhinav Seth, Yong K. Kwon, Hassan Aziz Journal of Surgical Oncology.2023; 128(8): 1320. CrossRef
First
Prev
